MRNA Vaccines for Infectious Diseases - Advances, Challenges and Opportunities

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2024 Oct 4

PMID 39367276

Authors

Norbert Pardi

Florian Krammer

Affiliations

Soon will be listed here.

Abstract

The concept of mRNA-based vaccines emerged more than three decades ago. Groundbreaking discoveries and technological advancements over the past 20 years have resolved the major roadblocks that initially delayed application of this new vaccine modality. The rapid development of nucleoside-modified COVID-19 mRNA vaccines demonstrated that this immunization platform is easy to develop, has an acceptable safety profile and can be produced at a large scale. The flexibility and ease of antigen design have enabled mRNA vaccines to enter development for a wide range of viruses as well as for various bacteria and parasites. However, gaps in our knowledge limit the development of next-generation mRNA vaccines with increased potency and safety. A deeper understanding of the mechanisms of action of mRNA vaccines, application of novel technologies enabling rational antigen design, and innovative vaccine delivery strategies and vaccination regimens will likely yield potent novel vaccines against a wide range of pathogens.

Citing Articles

RNA vaccines: The dawn of a new age for tuberculosis?.

Li J, Liu D, Li X, Wei J, Du W, Zhao A Hum Vaccin Immunother. 2025; 21(1):2469333.

PMID: 40013818 PMC: 11869779. DOI: 10.1080/21645515.2025.2469333.

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

Regulating Immune Responses Induced by PEGylated Messenger RNA-Lipid Nanoparticle Vaccine.

Jo H, Jeoung J, Kim W, Jeoung D Vaccines (Basel). 2025; 13(1).

PMID: 39852793 PMC: 11768904. DOI: 10.3390/vaccines13010014.

Comparative Analysis of Virology and Pathogenesis of SARS-CoV-2 and HIV Infections: Implications for Public Health and Treatment Strategies.

Olebo D, Igwe M Infect Drug Resist. 2025; 18():269-283.

PMID: 39835166 PMC: 11742764. DOI: 10.2147/IDR.S498430.

Platform Technology in Global Vaccine Regulation: Development, Applications, and Regulatory Strategies with Insights from China.

Li X, Jin S, Guo S, Yang D, Sai W, Qiu X Vaccines (Basel). 2025; 12(12.

PMID: 39772096 PMC: 11728622. DOI: 10.3390/vaccines12121436.

References

Shattock A, Johnson H, Sim S, Carter A, Lambach P, Hutubessy R . Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet. 2024; 403(10441):2307-2316. PMC: 11140691. DOI: 10.1016/S0140-6736(24)00850-X. View

Pollard A, Bijker E . A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2020; 21(2):83-100. PMC: 7754704. DOI: 10.1038/s41577-020-00479-7. View

Freyn A, Silva J, Rosado V, Bliss C, Pine M, Mui B . A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol Ther. 2020; 28(7):1569-1584. PMC: 7335735. DOI: 10.1016/j.ymthe.2020.04.018. View

John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw C . Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018; 36(12):1689-1699. DOI: 10.1016/j.vaccine.2018.01.029. View

McMahon M, ODell G, Tan J, Sarkozy A, Vadovics M, Carreno J . Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc Natl Acad Sci U S A. 2022; 119(45):e2206333119. PMC: 9659346. DOI: 10.1073/pnas.2206333119. View

Pardi N, Carreno J, ODell G, Tan J, Bajusz C, Muramatsu H . Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat Commun. 2022; 13(1):4677. PMC: 9362976. DOI: 10.1038/s41467-022-32149-8. View

Sajid A, Matias J, Arora G, Kurokawa C, DePonte K, Tang X . mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Sci Transl Med. 2021; 13(620):eabj9827. DOI: 10.1126/scitranslmed.abj9827. View

Arevalo C, Bolton M, Le Sage V, Ye N, Furey C, Muramatsu H . A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022; 378(6622):899-904. PMC: 10790309. DOI: 10.1126/science.abm0271. View

Tseng H, Ackerson B, Sy L, Tubert J, Luo Y, Qiu S . mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023; 14(1):5851. PMC: 10511551. DOI: 10.1038/s41467-023-41537-7. View

10.

Harris E . Combined COVID-19, Flu Vaccine Candidate Headed to Phase 3 Trials. JAMA. 2023; 330(21):2044. DOI: 10.1001/jama.2023.22353. View

11.

Ye Q, Wu M, Zhou C, Lu X, Huang B, Zhang N . Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines. 2022; 7(1):84. PMC: 9315335. DOI: 10.1038/s41541-022-00478-w. View

12.

Daniel S, Kis Z, Kontoravdi C, Shah N . Quality by Design for enabling RNA platform production processes. Trends Biotechnol. 2022; 40(10):1213-1228. DOI: 10.1016/j.tibtech.2022.03.012. View

13.

Warne N, Ruesch M, Siwik P, Mensah P, Ludwig J, Hripcsak M . Delivering 3 billion doses of Comirnaty in 2021. Nat Biotechnol. 2023; 41(2):183-188. DOI: 10.1038/s41587-022-01643-1. View

14.

Alameh M, Weissman D, Pardi N . Messenger RNA-Based Vaccines Against Infectious Diseases. Curr Top Microbiol Immunol. 2020; 440:111-145. DOI: 10.1007/82_2020_202. View

15.

Blakney A, Ip S, Geall A . An Update on Self-Amplifying mRNA Vaccine Development. Vaccines (Basel). 2021; 9(2). PMC: 7911542. DOI: 10.3390/vaccines9020097. View

16.

Lutz J, Lazzaro S, Habbeddine M, Schmidt K, Baumhof P, Mui B . Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines. 2017; 2:29. PMC: 5648897. DOI: 10.1038/s41541-017-0032-6. View

17.

Petsch B, Schnee M, Vogel A, Lange E, Hoffmann B, Voss D . Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012; 30(12):1210-6. DOI: 10.1038/nbt.2436. View

18.

Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller S, Petsch B . mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 2021; 6(1):57. PMC: 8052455. DOI: 10.1038/s41541-021-00311-w. View

19.

Kremsner P, Ahuad Guerrero R, Arana-Arri E, Aroca Martinez G, Bonten M, Chandler R . Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2021; 22(3):329-340. PMC: 8610426. DOI: 10.1016/S1473-3099(21)00677-0. View

20.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View